Please provide your email address to receive an email when new articles are posted on . Y-90 resin microspheres are the only approved radioembolization therapy for hepatic cellular carcinoma and ...

NICE recommends SIR-Spheres® Y-90 microspheres as an option for treating unresectable advanced hepatocellular carcinoma (HCC) in adults WOBURN, Mass., Feb. 26, 2021 /PRNewswire/ -- Sirtex Medical US ...

First prospective multicenter U.S.-based trial for indication expansion of SIR-Spheres ® Y-90 resin microspheres taking place in 15 sites across the U.S. WOBURN, Mass., May 10, 2021 /CNW/ -- Sirtex ...

Chicago, IL, USA (30 May 2015) -- The benefits of adding liver-directed SIR-Spheres Y-90 resin microspheres to a current systemic chemotherapy for the first-line treatment of unresectable metastatic ...

Sirtex announces SIR-Spheres ® portfolio expansion to include the FLEXdose SELECT 3mL vial configuration allowing for more patient-specific Y-90 selective treatment plans ...

Expanded indication makes SIR-Spheres ® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, ...

It took nearly 25 years, but advances in technology — an investigator’s insight — and a device company’s “leap of faith” have led to a major step forward in the treatment of unresectable ...

Phase II study with docetaxel (D), cisplatin (C), and continuous capecitabine (CAP) combination (TCX) in advanced gastric cancer: Preliminary data. This is an ASCO Meeting Abstract from the 2011 ASCO ...

Sirtex brings an innovative liver cancer treatment delivery system to Europe, enhancing options for physicians and their patients. WOBURN, Mass., Sept. 16, 2024 /CNW/ -- Sirtex Medical ("Sirtex"), a ...

Phase II study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers. This is an ASCO Meeting Abstract from the 2021 Gastrointestinal Cancers Symposium.